Across the recent three months, 7 analysts have shared their insights on Castle Biosciences (NASDAQ:CSTL), expressing a variety of opinions spanning from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 3 | 4 | 0 | 0 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 0 | 0 | 0 | 0 | 0 |
| 2M Ago | 1 | 3 | 0 | 0 | 0 |
| 3M Ago | 2 | 0 | 0 | 0 | 0 |
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $40.29, with a high estimate of $44.00 and a low estimate of $36.00. This upward trend is evident, with the current average reflecting a 14.17% increase from the previous average price target of $35.29.
Exploring Analyst Ratings: An In-Depth Overview
The analysis of recent analyst actions sheds light on the perception of Castle Biosciences by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Mason Carrico | Stephens & Co. | Maintains | Overweight | $41.00 | $41.00 |
| Sung Ji Nam | Scotiabank | Raises | Sector Outperform | $44.00 | $37.00 |
| Thomas Flaten | Lake Street | Raises | Buy | $40.00 | $34.00 |
| Paul Knight | Keybanc | Raises | Overweight | $36.00 | $28.00 |
| Catherine Ramsey | Baird | Raises | Outperform | $39.00 | $37.00 |
| Kyle Mikson | Canaccord Genuity | Lowers | Buy | $42.00 | $35.00 |
| Sung Ji Nam | BTIG | Raises | Buy | $40.00 | $35.00 |
Key Insights: Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Castle Biosciences. This information provides a snapshot of how analysts perceive the current state of the company. Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Castle Biosciences compared to the broader market. Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Castle Biosciences's stock. This comparison reveals trends in analysts' expectations over time.
Capture valuable insights into Castle Biosciences's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
Stay up to date on Castle Biosciences analyst ratings.
If you are interested in following small-capstock newsand performance you can start by tracking it here.
Delving into Castle Biosciences's Background
Castle Biosciences Inc is a commercial-stage dermatological cancer company. It is focused on providing physicians and their patients with personalized, clinically actionable genomic information to make more accurate treatment decisions. The product portfolio of the company includes Cutaneous Melanoma, DecisionDx-Melanoma, DecisionDx-CMSeq, and DecisionDx-PRAME among others.
Financial Milestones: Castle Biosciences's Journey
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining Castle Biosciences's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 39.5% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Castle Biosciences's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 2.65%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 0.52%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 0.45%, the company showcases effective utilization of assets.
Debt Management: With a below-average debt-to-equity ratio of 0.06, Castle Biosciences adopts a prudent financial strategy, indicating a balanced approach to debt management.
The Basics of Analyst Ratings
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in Benzinga Pro.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. Click here for urgent details.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Latest Ratings for CSTL
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jan 2022 | Stephens & Co. | Initiates Coverage On | Overweight | |
| Nov 2021 | SVB Leerink | Maintains | Outperform | |
| Jul 2021 | SVB Leerink | Maintains | Outperform |
View More Analyst Ratings for CSTL
View the Latest Analyst Ratings
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
